Online inquiry

IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3549MR)

This product GTTS-WQ3549MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MIF gene. The antibody can be applied in Inflammatory conditions research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002415.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4282
UniProt ID P14174
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3549MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6255MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ10878MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ14191MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ9609MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ5411MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ898MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ7351MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ663MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 8H9
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW